Tivic Health Systems Inc. delivered an invited presentation at a TechWatch meeting with the Biomedical Advanced Research and Development Authority (BARDA), along with members of the Department of Defense, Defense Threat Reduction Agency, National Institutes of Health, and National Institute of Allergy and Infectious Diseases. During the event, Tivic showcased clinical and manufacturing readiness data for its Toll-like Receptor 5 (TLR5) agonist, Entolimod, highlighting its potential as a radiation countermeasure and its accelerated development through subsidiary Velocity Bioworks. The presentation initiated discussions about the possible inclusion of Entolimod in the Strategic National Stockpile, with BARDA requesting a follow-up meeting to further explore its utility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1131169) on January 28, 2026, and is solely responsible for the information contained therein.